Compass Pathways's book value per share for the quarter that ended in Mar. 2024 was €3.49.
During the past 12 months, Compass Pathways's average Book Value Per Share Growth Rate was 0.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Compass Pathways was -12.70% per year. The lowest was -12.70% per year. And the median was -12.70% per year.
Compass Pathways's current price is €6.20. Its book value per share for the quarter that ended in Mar. 2024 was €3.49. Hence, today's PB Ratio of Compass Pathways is 1.78.
During the past 6 years, the highest P/B Ratio of Compass Pathways was 8.25. The lowest was 0.00. And the median was 0.00.
Compass Pathways Book Value per Share Historical Data
The historical data trend for Compass Pathways's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Compass Pathways's Book Value per Share
For the Medical Care Facilities subindustry, Compass Pathways's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways's PB Ratio Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's PB Ratio distribution charts can be found below:
* The bar in red indicates where Compass Pathways's PB Ratio falls into.
Compass Pathways Book Value per Share Calculation
Compass Pathways's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Compass Pathways (FRA:5Y6) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Compass Pathways Book Value per Share Related Terms
Thank you for viewing the detailed overview of Compass Pathways's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:5Y6 has been successfully added to your 